 |
| 07-Mar-11 | Downgrade |
Rodman & Renshaw |
Mkt Outperform → Mkt Perform |
|
|
| 30-Jun-09 | Initiated |
Merriman |
Buy |
|
|
| 12-Jun-08 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
$11 → $9 |
|
| 10-Sep-07 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
$6 → $8 |
|
| 12-Apr-07 | Reiterated |
Rodman & Renshaw |
Mkt Outperform |
$5 → $6 |
|
|
|
| 18-Jun-13 09:50AM | Why Repligen Is Ready to Rebound at Motley Fool |
| 23-May-13 01:39PM | Repligen CEO to Present at Jefferies 2013 Global Healthcare Conference GlobeNewswire |
| 14-May-13 01:04PM | REPLIGEN CORP Financials EDGAR Online Financials |
| 10-May-13 03:34PM | Repligen Stock Sees Short Interest Move 24.7% Higher at Forbes |
| 09:32AM | REPLIGEN CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online |
| 07-May-13 06:56AM | REPLIGEN CORP Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 03-May-13 11:55PM | Repligen's CEO Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 02-May-13 09:00AM | Repligen Corporation Earnings Call scheduled for 9:00 am ET today CCBN |
| 07:36AM | InPlay: Repligen reports Q1 results, revs rose 28% YoY to $16.5 mln, provides guidance for 2013 Briefing.com |
| 07:30AM | Repligen Reports First Quarter 2013 Financial Results GlobeNewswire |
| 07:07AM | Q1 2013 Repligen Corporation Earnings Release - Before Market Open CCBN |
| 01:48AM | REPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 01-May-13 11:32AM | Incremental Changes in Regulatory Environment Beneficial to Development-Stage Biotech Companies Due to Emphasis on Closer Working Relationships with the FDA and Drug Sponsors Wall Street Transcript |
| 24-Apr-13 04:40PM | Isis Pharma's ISIS-SMNRx Progresses Zacks |
| 23-Apr-13 05:35PM | Repligen to Report First Quarter 2013 Financial Results GlobeNewswire |
| 05-Apr-13 06:09PM | Nasdaq stocks posting largest percentage increases AP |
| 02:26PM | Nasdaq stocks posting largest percentage increases AP |
| 04-Apr-13 06:03PM | Nasdaq stocks posting largest percentage increases AP +10.26% |
| 01:33PM | Nasdaq stocks posting largest percentage increases AP |
| 02-Apr-13 03:59PM | Repligen Promises To Be A Cash Flow Machine at Seeking Alpha |
| 20-Mar-13 01:04PM | REPLIGEN CORP Financials EDGAR Online Financials |
| 15-Mar-13 10:16AM | REPLIGEN CORP Files SEC form 10-K, Annual Report EDGAR Online |
| 07-Mar-13 10:50AM | Repligen Management Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 09:00AM | Repligen Corporation Earnings Call scheduled for 9:00 am ET today CCBN |
| 09:00AM | Q4 and Yearend 2012 Repligen Corporation Earnings Call scheduled for 9:00 am ET today CCBN |
| 07:46AM | REPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 07:30AM | Repligen Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Financial Guidance for 2013 GlobeNewswire |
| 07:07AM | Q4 2012 Repligen Corporation Earnings Release - Before Market Open CCBN |
| 01-Mar-13 01:34PM | Repligen to Report Fourth Quarter and Full Year 2012 Financial Results GlobeNewswire |
| 14-Jan-13 12:43PM | Warren Isabelle: 2013 Will Be A Stock Picker's Market at Seeking Alpha |
| 10-Jan-13 12:45PM | Correction: Repligen-Pfizer story AP |
| 11:08AM | Positive Results on MDCO's Cangrelor Zacks |
| 09-Jan-13 05:54PM | Optimer's Dificid Sales Look Good Zacks |
| 05:23PM | Abbott's ABSORB in Phase III Trial Zacks |
| 08-Jan-13 06:08PM | Repligen, Pfizer Collaborate Zacks |
| 05:43PM | Aegerion Upbeat About 2013 Zacks |
| 05:03PM | Encouraging Prelim Results at DNDN Zacks |
| 07-Jan-13 05:48PM | AMAG Gives 4Q12 Snapshot Zacks |
| 04-Jan-13 06:15PM | BioMimetic's Pipeline Progresses Zacks |
| 08:48AM | Positive Data on Alkermes Candidate Zacks |
| 03-Jan-13 06:28PM | Coronado Amends Ovamed Agreement Zacks |
| 03:34PM | Zacks.com featured expert Kevin Matras highlights: Alliance Data Systems Corp., Gildan Activewear Inc., Lions Gate Entertainment Corp., Repligen Corp. and World Acceptance Corp. Zacks |
| 03:33PM | Pfizer Licenses Spinal Muscular Atrophy Program From Repligen at Motley Fool |
| 11:27AM | Repligen forms partnership on spinal muscle drug AP |
| 07:45AM | REPLIGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online |
| 07:34AM | Repligen enters into licensing agreement with Pfizer for SMA program at theflyonthewall.com |
| 07:30AM | InPlay: Repligen announces licensing agreement with Pfizer for spinal muscular atrophy program Briefing.com |
| 07:30AM | Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program Business Wire |
| 27-Dec-12 03:58PM | Dendreon Sells Manufacturing Unit Zacks |
| 03:38PM | AMAG Seeks Feraheme Label Expansion Zacks |
| 26-Dec-12 05:23PM | FDA Approves Aegerion's Juxtapid Zacks |
| 01:01PM | ALIOF Drug to Move into Phase III Zacks |
| 11-Dec-12 10:59AM | AMAG Presents Feraheme Data Zacks |
| 05-Dec-12 06:58AM | Repligen Is A Buy: You Don't Have To Mine Gold To Make Money In A Gold Rush at Seeking Alpha |
| 06:58AM | Repligen Is A Buy: You Don't Have To Mine Gold To Make Money In A Gold Rush at Seeking Alpha |
| 06:45AM | Repligen Is A Buy: You Don't Have To Mine Gold To Make Money In A Gold Rush at Seeking Alpha |
| 16-Nov-12 01:04PM | REPLIGEN CORP Financials EDGAR Online Financials |
| 11-Nov-12 10:03AM | Repligen Corp. Earnings: Higher-Than-Expected Net Income at Wall St. Cheat Sheet |
| 10-Nov-12 09:30AM | New Star Analyst Rankings for Repligen Corporation StarMine |
| 09-Nov-12 09:32AM | New Star Analyst Rankings for Repligen Corporation StarMine |
| 08-Nov-12 02:23PM | Healthcare Review: DUSA Pharmaceuticals, InterMune, Tekmira, BioScrip, Repligen Corporation, OraSure Are Notable Movers Thomson Reuters ONE +10.04% |
| 10:13AM | Repligen Corp. Earnings: Higher-Than-Expected Net Income at Wall St. Cheat Sheet |
| 09:00AM | Repligen Corporation Earnings Call scheduled for 9:00 am ET today CCBN |
| 08:53AM | Repligen Corp. Earnings: Higher-Than-Expected Net Income at Wall St. Cheat Sheet |
| 08:21AM | Repligen Corp. Earnings: Higher-Than-Expected Net Income at Wall St. Cheat Sheet |
| 07:45AM | REPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 07:36AM | Repligen Corporation Earnings Call scheduled for 9:00 am ET today CCBN |
| 07:30AM | Repligen Reports Third Quarter 2012 Financial Results Business Wire |
| 07:07AM | Q3 2012 Repligen Corporation Earnings Release - Before Market Open CCBN |
| 03:04AM | Repligen Corp Third Quarter Earnings Sneak Peek at Wall St. Cheat Sheet |
| 07-Nov-12 07:30AM | Repligen CEO to Present at Upcoming Investor Conferences Business Wire |
| 05-Nov-12 11:04AM | Repligen Corp Third Quarter Earnings Sneak Peek at Wall St. Cheat Sheet |
| 26-Oct-12 09:00AM | REPLIGEN CORP Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online |
| 07:30AM | Repligen To Report Third Quarter of 2012 Financial Results Business Wire |
| 16-Oct-12 08:08AM | Where We Are Headed - New Outlook on Stemcells, Inc. and Repligen Corporation Marketwire |
| 26-Sep-12 12:25PM | 5 Stocks With Big Insider Buying at TheStreet |
| 25-Sep-12 01:52PM | Tuesday 9/25 Insider Buying Report: RGEN, APU at Forbes |
| 05:19AM | Top 5 Stocks With Insider Buys Filed On September 24 To Consider at Seeking Alpha |
| 24-Sep-12 08:57AM | 3 Medical Growth Stocks Nearing All-Time Highs at Seeking Alpha |
| 21-Sep-12 03:23PM | CFO Moves: MicroVision, Progenics, Repligen at The Wall Street Journal |
| 08:31AM | REPLIGEN CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and E EDGAR Online |
| 08:08AM | Drug developer Repligen names new CFO AP |
| 06:30AM | InPlay: Repligen appoints Jonathan I. Lieber as CFO Briefing.com |
| 06:30AM | Repligen Appoints Jonathan I. Lieber as CFO Business Wire |
| 11-Sep-12 06:10PM | Nasdaq stocks posting largest percentage increases AP |
| 01:17PM | Nasdaq stocks posting largest percentage increases AP |
| 10-Sep-12 06:06PM | Nasdaq stocks posting largest percentage increases AP +12.10% |
| 01:17PM | Nasdaq stocks posting largest percentage increases AP |
| 29-Aug-12 07:30AM | Repligen to Present at Stifel Nicolaus Healthcare Conference 2012 Business Wire |
| 17-Aug-12 01:04PM | REPLIGEN CORP Financials EDGAR Online Financials |
| 16-Aug-12 01:09PM | 5 Stocks Under $10 Set to Soar at TheStreet +5.08% |
| 10-Aug-12 01:04PM | REPLIGEN CORP Financials EDGAR Online Financials |
| 09-Aug-12 10:49AM | REPLIGEN CORP Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 02-Aug-12 04:34PM | Health Care Sector Wrap at Fox Business +15.82% |
| 01:09PM | Repligen Earnings: Beats Wall Street Expectations at Wall St. Cheat Sheet |
| 08:30AM | Repligen Corporation Earnings Call scheduled for 8:30 am ET today CCBN |
| 08:16AM | Repligen Corporation Earnings Call scheduled for 8:30 am ET today CCBN |
| 07:39AM | REPLIGEN CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 07:36AM | Repligen Corporation Earnings Call scheduled for 8:30 am ET today CCBN |
| 07:30AM | Repligen Announces Strategic Focus on Bioprocessing Business and Reports Second Quarter 2012 Financial Results Business Wire |
|
|
| Repligen Corporation, a life sciences company, engages in the development, production, and commercialization of consumable products used in the process of manufacturing biological drugs. Its bioprocessing products are sold to various life sciences and biopharmaceutical companies worldwide. The company manufactures Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. It also supplies various growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, the company develops and markets its OPUS brand series of pre-packed plug-and-play' chromatography columns, and provides ELISA test kits to ensure final product quality. Further, Repligen has a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and a orphan drug candidate in Phase 1 development. The company was founded in 1981 and is headquartered in Waltham, Massachusetts. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| RYAN THOMAS F JR | Director | May 17 | Sale | 9.00 | 7,000 | 63,030 | 0 | May 20 12:04 PM | | RYAN THOMAS F JR | Director | May 17 | Sale | 8.95 | 10,000 | 89,524 | 48,380 | May 20 12:04 PM | | RYAN THOMAS F JR | Director | May 16 | Sale | 8.95 | 4,000 | 35,801 | 58,380 | May 20 12:04 PM | | RYAN THOMAS F JR | Director | May 15 | Option Exercise | 3.10 | 14,884 | 46,140 | 73,883 | May 15 03:21 PM | | RYAN THOMAS F JR | Director | May 15 | Sale | 8.96 | 14,884 | 133,423 | 58,999 | May 15 03:21 PM | | RYAN THOMAS F JR | Director | May 15 | Sale | 9.00 | 1,961 | 17,643 | 62,380 | May 16 02:16 PM | | HERLIHY WALTER C | PRESIDENT, CEO | May 15 | Sale | 8.85 | 1,514 | 13,399 | 537,793 | May 16 08:28 AM | | RYAN THOMAS F JR | Director | May 14 | Option Exercise | 3.38 | 15,116 | 51,060 | 76,038 | May 15 03:21 PM | | HERLIHY WALTER C | PRESIDENT, CEO | May 14 | Sale | 8.98 | 38,486 | 345,450 | 549,307 | May 16 08:28 AM | | RYAN THOMAS F JR | Director | May 14 | Sale | 8.95 | 17,155 | 153,490 | 58,999 | May 15 03:21 PM | | RYAN THOMAS F JR | Director | May 13 | Option Exercise | 5.99 | 54,000 | 323,490 | 100,038 | May 15 03:21 PM | | RYAN THOMAS F JR | Director | May 13 | Sale | 9.04 | 54,000 | 488,263 | 61,038 | May 15 03:21 PM | | Kelly William J | Chief Accounting Officer | May 07 | Option Exercise | 4.82 | 20,000 | 96,400 | 20,000 | May 08 02:46 PM | | Kelly William J | Chief Accounting Officer | May 07 | Sale | 9.14 | 20,000 | 182,734 | 0 | May 08 02:46 PM | | Benjamin Howard | VP Business Development | May 06 | Option Exercise | 3.85 | 22,964 | 88,397 | 26,731 | May 07 01:42 PM | | HERLIHY WALTER C | PRESIDENT, CEO | May 03 | Option Exercise | 4.59 | 150,000 | 688,700 | 627,838 | May 06 03:33 PM | | WITT DANIEL P | Senior Vice President | Mar 26 | Option Exercise | 5.51 | 10,000 | 55,100 | 55,707 | Mar 27 05:24 PM | | RUSCHE JAMES R | Senior Vice President | Mar 26 | Option Exercise | 5.51 | 25,000 | 137,750 | 167,121 | Mar 27 05:23 PM | | HERLIHY WALTER C | PRESIDENT, CEO | Mar 26 | Option Exercise | 5.51 | 65,000 | 358,150 | 566,898 | Mar 27 05:22 PM | | RUSCHE JAMES R | Senior Vice President | Sep 27 | Sale | 5.95 | 5,000 | 29,753 | 154,121 | Oct 02 02:15 PM | | COOPER GLENN L MD | Director | Sep 21 | Buy | 6.09 | 10,000 | 60,874 | 26,038 | Sep 24 04:11 PM | | Kelly William J | CFO | Aug 31 | Option Exercise | 4.65 | 90,000 | 418,900 | 95,000 | Sep 04 08:41 PM | | Kelly William J | CFO | Aug 31 | Sale | 5.52 | 95,000 | 524,460 | 0 | Sep 04 08:41 PM | | GRIFFITH MICHAEL A | Director | Aug 16 | Buy | 4.88 | 2,000 | 9,757 | 2,000 | Aug 20 03:00 PM |
|
|
|
|
|
|
